US · Healthcare · Biotechnology
EPS came in at -0.82 against a street estimate of -0.77 — a miss of 6.5%.
Analysts rate Bicara Therapeutics Inc. Common Stock a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $34.54.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 10.97% |
| T. Rowe Price Investment Management,Inc. | 9.98% |
| Siren, L.L.C. | 8.77% |
| Vestal Point Capital LP | 8.20% |
| Deep Track Capital, LP | 6.20% |
| HHG PLC | 5.05% |
| Red Tree Management, LLC | 4.78% |
| TPG GP A, LLC | 4.55% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 BICARA THERAPEUTICS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company entered into Sub-Sublease Agreement on August 21, 2026 for new corporate head | 2026-08-25 |
| Quarterly report · Q2 2026 BICARA THERAPEUTICS INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and marketable securities combined: $497.3 million as of June 30, 2026 (up f | 2026-08-11 |
| Results announced · Q3 2026 BICARA THERAPEUTICS INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and marketable securities: $497.3 million as of June 3 | 2026-08-11 |
| Board / officer change · Q3 2026 BICARA THERAPEUTICS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 9 to 10 directors, effective July 28, 2026 • Two new indepe | 2026-07-28 |
| Shareholder vote results · Q2 2026 BICARA THERAPEUTICS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 9, 2026 • 65,600,370 total shares outstanding as | 2026-06-10 |
| Quarterly report · Q1 2026 BICARA THERAPEUTICS INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $323.5 million in cash and cash equivalents plus $216.3 million in | 2026-05-11 |
| Proxy statement · Q2 2026 BICARA THERAPEUTICS INC. — PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of 2 Class II Directors to serve until the 2029 | 2026-04-27 |
| Annual report FY2025 BICARA THERAPEUTICS INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Bicara Therapeutics Inc., clinical-stage biopharmaceut | 2026-03-30 |
Readable in the app.
| Announcement | Date |
|---|---|
| Phase 3 optimal dose announcement and 2026 corporate outlook provided Bicara Therapeutics announced on January 12, 2026, that it has identified the optimal dose for its Phase 3 clinical trial and provided its 2026 corporate outlook. This is a significant miles | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bicara Therapeutics Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.